Akriveia Therapeutics LLC, a Thousand Oaks, Calif.-based immuno-oncology focused biotechnology company, raised $7.5m in Series A funding.
The round was led by F-Prime Capital Partners. Thomas Beck and Ben Auspitz of F-Prime Capital Partners will join Akriveia’s Board of Directors in conjunction with the funding. Dr. Beck will become Chairman of the Board.
The company intends to use the funds to expand the team to accelerate its therapeutic discovery efforts, and to build a pipeline of single agent and combination immunotherapeutics.
Led by Chief Executive Officer Simon Tomlinson, Akriveia Therapeutics leverages its proprietary platform to create immunotherapeutic products that are specifically activated in the microenvironment of the tumor. To this end, the company also announced that it has entered into exclusive license agreements for key enabling technologies with City of Hope and Thomas Jefferson University.
Akriveia was founded on the work of Professor John Williams at City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, experts in the fields of bioengineering and cancer therapeutic discovery.